TAM
CYCN icon

Tiverton Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

Tiverton Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$51K Hold
210
– – ﹤0.01% 689
2019
Q2 		$48K Buy
+210
New +$59.4K ﹤0.01% 666

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Tiverton Asset Management's CYCN Position: Q3 2019 in Review

Tiverton Asset Management held its Cyclerion Therapeutics (CYCN) position steady in Q3 2019 at 210 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #689.

Tiverton Asset Management first reported a position in CYCN in Q2 2019 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CYCN as of Q3 2019.

  • Tiverton Asset Management held 210 shares of Cyclerion Therapeutics worth $51K as of Q3 2019.
  • Tiverton Asset Management left its Cyclerion Therapeutics share count unchanged in Q3 2019.
  • Cyclerion Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #689 holding.
  • Tiverton Asset Management first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.